Amsterdam Molecular Thrputcs AMT Hldg NV  

(Public, AMS:AMT)   Watch this stock  
Find more results for AMT
0.0000
Delayed:  
AMS data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.00 - 0.74
Open     -
Vol / Avg. 0.00/181,901.00
Mkt cap     -
P/E     -
Div/yield     -
EPS 0.00
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '11) 2011
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 171.53% 0.00%
Return on average equity 1419.04% 0.00%
Employees 85 -
CDP Score - -

Address

Meibergdreef 61
AMSTERDAM, 1105 BA
Netherlands
+31-20-5667394 (Phone)
+31-20-5669272 (Fax)

Website links

Description

Amsterdam Molecular Therapeutics AMT Holding NV is a Netherlands-based company, which was formerly engaged in human gene therapy. The Company developed Glybera, for the treatment of Lipoprotein Lipase Deficiency (LPLD). On April 5, 2012, the Company disposed of its entire business and operations to uniQure B.V., and as of this date, the Company was in liquidation.